Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:05 PM.
Here’s what investors need to know about the announcement.
Earnings
Myriad Genetics missed estimated earnings by 10.53%, reporting an EPS of $-0.21 versus an estimate of $-0.19.
Revenue was up $16.30 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.04 which was followed by a 13.21% increase in the share price the next day.
Here’s a look at Myriad Genetics’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.16 | -0.06 | 0.01 | -0.07 |
| EPS Actual | -0.12 | -0.19 | 0.04 | -0.03 |
| Revenue Estimate | 169.46M | 170.10M | 171.00M | 156.62M |
| Revenue Actual | 177.80M | 156.40M | 179.30M | 164.90M |
To track all earnings releases for Myriad Genetics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
